The Valley Desk

Clinical trial reportCancer immunology, immunotherapy : CIIPublished

A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Cancer immunology, immunotherapy : CII
Published
Subject terms
Humans; Neoplasms; Injections, Subcutaneous; Adult; Aged; Middle Aged; Female; Male; Antibodies, Monoclonal, Humanized; Programmed Cell Death 1 Receptor; Antineoplastic Agents, Immunological; Immune Checkpoint Inhibitors
PubMed ID
42313189
PubMed Central ID
PMC13522328
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal